- Immunic, Inc (NASDAQ:IMUX) reported data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset, vidofludimus calcium (IMU-838), in patients with moderate-to-severe ulcerative colitis (UC).
- Data showed a dose-linear increase in clinical remission as compared to placebo at week 50.
- An exploratory statistical analysis confirmed the 30 mg dose of vidofludimus calcium to be statistically superior (p=0.0358) in achieving clinical remission at week 50, with a 33.7% absolute improvement over the placebo.
- Related: Immunic Touts Positive Vidofludimus Calcium Data In Multiple Sclerosis Candidate.
- A dose-linear increase in endoscopic healing was observed, with the 30 mg dose of vidofludimus calcium being associated with a 37.8% absolute improvement over the placebo.
- Immunic says the maintenance phase data of CALDOSE-1 confirms vidofludimus calcium’s activity in the absence of chronic corticosteroid co-administration.
- Immunic has decided to focus its resources on vidofludimus calcium and IMU-856, deprioritizing the clinical portion of its izumerogant development program in psoriasis and castration-resistant prostate cancer.
- For IMU-856, the part C portion of the ongoing phase 1 trial in celiac disease patients has been proceeding more quickly than anticipated, with initial data expected to become available in the current quarter.
- Price Action: IMUX shares are up 11% at $1.62 on the last check Wednesday.
‘Credit Suisse Appeals To Swiss Central Bank For Show Of Support As Share Slide Sparks Wider Rout’ – Financial Times
https://www.ft.com/content/0324c5a6-cecd-4fb3-85b3-7cdc99a33e4e
